Halún-Treviño AN, González-Bonilla EA, Barrera-Juárez E, González-Oyervides R

Language: Spanish
References: 12
Page: 1-6
PDF size: 291.04 Kb.

ABSTRACT

Clinical case description: A 64-year-old woman with an unremarkable past medical history was evaluated due to lower urinary tract symptoms and hematuria of 1-month progression. A magnetic resonance imaging scan revealed a lesion consistent with urethral tumor. During urethrocystoscopy, a tumor was found inside a urethral diverticulum. Transurethral resection was carried out, followed by the later performance of anterior pelvic exenteration. The histopathologic result was clear cell adenocarcinoma inside a proximal urethral diverticulum. The patient did not undergo adjuvant therapy, remaining in follow-up and surveillance, and is presently recurrence-free.
Relevance: Urethral carcinoma is an uncommon tumor and its appearance in a diverticulum is rare. Those types of tumor are highly invasive and require aggressive treatment to offer the possibility of cure.
Clinical implications: No standardized treatment is in place. Surgical treatment through radical urethrectomy or anterior pelvic exenteration, with or without adjuvant therapy, is the most widely accepted therapeutic option.
Conclusions: Clear cell adenocarcinoma arising in a urethral diverticulum is uncommon and usually has a locally advanced presentation. There is no standardized treatment or follow-up for the disease.

REFERENCES

1. Sharp D S, Angermeier K. Tumors of the urethra. In: Campbell-Walsh Urology. 11th ed. Elsevier; 2016. p. 4168.

2. Gheiler EL, Tefilli MV, Tiguert R, de Oliveira JG, Pontes JE, Wood DP. Management of primary urethral cancer. Urology. 1998;52(3):487–93. doi: 10.1016/s0090-4295(98)00199-x

3. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012 Mar;48(4):456–64. doi: 10.1016/j. ejca.2011.10.031

4. Collado A, Algaba F, Caparrós J, Alberola J, Montlleó M, Arañó P, et al. Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. Scandinavian Journal of Urology and Nephrology. 2000;34(2):136–8. doi: 10.1080/003655900750016779

5. Peven DR, Hidvegi DF. Clear-cell adenocarcinoma of the female urethra. Acta Cytol. 1985;29(2):142–6.

6. Kawano K, Yano M, Kitahara S, Yasuda K. Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostatespecific antigen. BJU Int. 2001;87(4):412–3. doi: 10.1046/j.1464-410x.2001.00126.x

7. Rajan N, Tucci P, Mallouh C, Choudhury M. Carcinoma in female urethral diverticulum: case reports and review of management. J Urol. 1993;150(6):1911–4. doi: 10.1016/s0022- 5347(17)35933-5

8. Touijer AK, Dalbagni G. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology. 2004;63(1):33–5. doi: 10.1016/j.urology.2003.08.007

9. Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol Clin North Am. 2010;37(3):445–57. doi: 10.1016/j. ucl.2010.04.011

10. Thüroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, et al. EAU guidelines on urinary incontinence. Eur Urol. 2011;59(3):387–400. doi: 10.1016/j. eururo.2010.11.021

11. Drew PA, Murphy WM, Civantos F, Speights VO. The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum Pathol. 1996;27(3):248– 52. doi: 10.1016/s0046-8177(96)90064-7

12. Gakis G, Daneshmand S, Efstathiou JA, Ali- El-Dein B, Hrbacek J, Keegan KA, et al. 822 Prognostic factors and outcomes after definitive treatment for primary urethral cancer: Results from the International Collaboration on Primary Urethral Carcinoma (ICPUC). European Urology Supplements. 2013;12(1):e822–3. doi: 10.1016/S1569-9056(13)61302-0